Why is Glenmark Pharma falling/rising?

As of 15-Jul, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, currently at Rs 2,230.50, which reflects a rise of 12.3 points or 0.55%. The stock has shown strong performance recently, gaining 22.5% over the last four days and is only 2.49% away from its 52-week high of Rs 2,286.15. Despite this upward trend, the stock underperformed its sector by 0.7% today, and there was a notable decline in investor participation, with delivery volume falling by 42.27% compared to the five-day average. However, the company has demonstrated a robust ability to service debt, evidenced by a low Debt to EBITDA ratio of 1.00 times, and has reported positive results for the last four consecutive quarters, including a remarkable 576.7% growth in PAT for the latest quarter.
In the broader market context, Glenmark Pharmaceuticals has significantly outperformed the benchmark Sensex, with a 1-week return of +22.27% compared to the benchmark's -1.36%, and a year-to-date return of +38.64% versus the Sensex's +5.67%. This consistent outperformance over various periods, including a 58.75% return over the last year, indicates strong investor confidence, particularly from institutional investors who hold 37.8% of the stock. The stock's liquidity remains adequate for trading, further supporting its positive momentum despite the recent dip in trading volume.